1.1 Billion COVID-19 Vaccines Sold by Maryland Firm
Gaitherburg-based Novavax, Inc. announced an agreement with Gavi, the Vaccine Alliance (Gavi), to provide 1.1 billion cumulative doses of NVX-CoV2373, Novavax’ recombinant protein-based COVID-19 vaccine candidate, for the COVAX Facility.
COVAX is the vaccines pillar of the Access to COVID-19 Tools Accelerator, which includes more than 190 participating economies.
The vaccine doses for this Memorandum of Understanding will be manufactured and distributed globally by Novavax and Serum Institute of India (SII), the latter under an existing agreement between Gavi and SII.
“We are pleased to deepen our partnership with Novavax and COVAX to increase the doses of vaccine available to benefit humanity,” said Adar Poonawalla, CEO, SII. ”This global collaboration is vital to ensure that the largest possible amount of vaccine is available to reach individuals across the broadest segment of countries."
NVX-CoV2373 was the first vaccine to demonstrate clinical efficacy against the original strain of COVID-19 and both of the rapidly emerging variants in the United Kingdom and South Africa. NVX-CoV2373 can neither cause COVID-19 nor can it replicate.
It is shipped in a ready-to-use liquid formulation. Because it is stable at 2°C to 8°C (refrigerated), existing vaccine supply chain channels can be used for its distribution, says the company.